nContact’s Cardiac Ablation Technology to be Highlighted in Three Presentations at Heart Rhythm 2012
MORRISVILLE, N.C., May 2, 2012 /PRNewswire/ — nContact, Inc., the leading innovator in epicardial ablation devices, today announced its technology will be included in an oral presentation during an abstract session and two poster presentations at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions, May 9-12 in Boston, MA.
nContact’s Numeris® Coagulation System with VisiTrax® and EPi-Sense(TM) Coagulation System technology integrates suction, perfusion, and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart. Access to the posterior of the atrium is achieved with a unique trans-diaphragmatic approach for minimally invasive, closed-chest epicardial ablation.
The following presentations will include the utilization of nContact’s technology:
Abstract Plus Session 35-02: Oral Presentation: “Combined Epicardial and Endocardial Ablation for Atrial Fibrillation: Single Center Experience in 100 Consecutive Patients”
Friday, May 11, 1:30 – 3:00 p.m.
Presented by: Kenneth C. Civello, MD, MPH, Our Lady of the Lake Medical Center, Baton Rouge, LA.
Poster Session IV #67: “Preliminary Outcomes of a new Epicardial/Endocardial Ablation Procedure (Convergent) for the Treatment of Atrial Fibrillation”
Friday, May 11, 9:30 a.m. – 12:00 p.m.
Presented by: Keith M. Golden, MD, St. Vincent Hospital, Indianapolis, IN
Poster Session VI #82: “Collaboration of Cardiac Surgery and Electrophysiology to Treat Atrial Fibrillation: Convergent Procedure Outcomes from a Single Center”
Saturday, May 12, 9:30 a.m. – 12:00 p.m.
Presented by: David M. Gilligan, MD, Levinson Heart Hospital at CJW Medical Center, Richmond, VA
About nContact, Inc.
nContact, Inc. is the leading innovator in epicardial ablation devices and techniques. Its mission is to transform the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias.
Its lead technologies, the EPi-Sense(TM) and Numeris® Coagulation System with VisiTrax®, have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.
The Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. The EPi-Sense(TM) device is not available in the United States. nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, U.S.A.
Media Contacts Beth Rose Kimberly Muscara nContact, Inc The Ruth Group T (919)655-1566 T (646) 536-7011 firstname.lastname@example.org email@example.com
SOURCE nContact, Inc.